Dactolisib

Overview

Dactolisib (BEZ235) is an orally active and dual pan-class I PI3K and mTOR kinase inhibitor with IC 50 s of 4 nM/5 nM/7 nM/75 nM, and 20.7 nM for p110α / p110γ / p110δ / p110β and mTOR , respectively. Dactolisib (BEZ235) inhibits both mTORC1 and mTORC2 .

Application

Products | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Autophagy | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PI3K | Products > Signaling Pathways > mTOR | Products > Signaling Pathways > Autophagy

Product Information

• Catalog No.: HY-50673
• CAS No.: 915019-65-7
• Molecular Formula: C30H23N5O
• Molecular Weight: 469.54
• Purity: 99.94%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 0.52 mg/mL (1.11 mM); Clear solution
• Availability: In-stock

Source

Original product source